Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Payables: 2010-2025

Historic Payables for BIO-TECHNE (TECH) over the last 16 years, with Jun 2025 value amounting to $25.3 million.

  • BIO-TECHNE's Payables fell 4.44% to $30.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.2 million, marking a year-over-year decrease of 7.47%. This contributed to the annual value of $25.3 million for FY2025, which is 33.34% down from last year.
  • According to the latest figures from FY2025, BIO-TECHNE's Payables is $25.3 million, which was down 33.34% from $38.0 million recorded in FY2024.
  • In the past 5 years, BIO-TECHNE's Payables registered a high of $38.0 million during FY2024, and its lowest value of $25.3 million during FY2025.
  • Its 3-year average for Payables is $29.7 million, with a median of $25.7 million in 2023.
  • In the last 5 years, BIO-TECHNE's Payables skyrocketed by 47.86% in 2024 and then plummeted by 33.34% in 2025.
  • BIO-TECHNE's Payables (Yearly) stood at $29.4 million in 2021, then climbed by 15.25% to $33.9 million in 2022, then declined by 24.17% to $25.7 million in 2023, then soared by 47.86% to $38.0 million in 2024, then slumped by 33.34% to $25.3 million in 2025.